Skip to content

Lidocaine-prilocaine cream versus lidocaine injection for top-up for pain relief during episiotomy repair after vaginal delivery at the University of Maiduguri Teaching Hospital: a randomised controlled trial

Lidocaine-prilocaine cream versus lidocaine injection for top-up for pain relief during episiotomy repair after vaginal delivery at the University of Maiduguri Teaching Hospital: a randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202508902692676
Enrollment
80
Registered
2025-08-07
Start date
2025-10-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

Sponsors

Dr Edward Sunday the researcher. No other sponsoship for the research
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: The following inclusion criteria will be applied: 1) Gestational age greater than or equal to 37 weeks 2) Singleton pregnancy 3) Cephalic presentation/ Vertex

Exclusion criteria

Exclusion criteria: The following criteria will be excluded: 1) Epidural analgesia 2) Operative delivery 3) Previous adverse reaction to a local anaesthetic 4) Cervical tear 5) 3rd or 4th degree perineal tear 6) Neurological disease which affects the lower limb 7) Heart disease 8) Uncontrolled Diabetes mellitus

Design outcomes

Primary

MeasureTime frame
The primary outcome of this study is to determine and compare participant pain perception when either lidocaine cream or lidocaine infiltration is given for top-up for pain relief during episiotomy repair following vaginal delivery.

Secondary

MeasureTime frame
The secondary outcome measures will be the need for rescue analgesia, duration of repair with each method, patient’s satisfaction, rate of adverse effects of both medications and post-partum complications (wound infection).

Countries

Nigeria

Contacts

Public ContactAbraham Okoihue

Drugfield pharmaceutical company drug representative

aokoihue@gmail.com+2348063176288

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026